SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 4)
MedQuist Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
584949101
--------------------------------------------------------------------------------
(CUSIP Number)
Neil T. Anderson, Esq.
Sullivan & Cromwell LLP
125 Broad Street
New York, New York 10004-2498
(212) 558-4000
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
July 6, 2007
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If a filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d- 1(g), check
the following box [ ].
--------------------------------------------------------------------------------
CUSIP NO. 584949101
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON
Koninklijke Philips Electronics N.V.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
222531298
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. SOURCE OF FUNDS
OO
--------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
[_]
--------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
The Netherlands
--------------------------------------------------------------------------------
7. SOLE VOTING POWER
NUMBER OF 26,085,086
SHARES --------------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 26,085,086
WITH --------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
26,085,086
--------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
[_]
--------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
69.6%
--------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
-2-
Item 1. Security and Issuer.
This Amendment No. 4 relates to the common stock, no par value (the
"Shares") of MedQuist Inc., a New Jersey corporation ("MedQuist"). This
Amendment No. 4 amends and supplements Items 4 and 5 of the Statement on
Schedule 13D dated June 6, 2000 (the "Schedule 13D") filed by Koninklijke
Philips Electronics N.V., a corporation incorporated under the laws of The
Netherlands ("Philips"), as previously amended and supplemented by Amendment No.
1 to the Schedule 13D, dated July 28, 2000, Amendment No. 2 to the Schedule 13D,
dated August 2, 2000 and Amendment No. 3 to the Schedule 13D, dated August 24,
2000. Unless otherwise defined herein, all capitalized terms used herein shall
have the meanings ascribed to them in the Schedule 13D.
Item 4. Purpose of Transaction.
Item 4 is hereby amended and supplemented as follows:
On July 6, 2007, Philips publicly announced that it is reviewing all of
its options with respect to its ownership interest in MedQuist following a
determiniation by Philips that it views its MedQuist ownership interest as a
non-core holding. In connection with such review, Philips may consider possible
transactions or other changes in its MedQuist ownership interest. However, no
specific plans or proposals currently exist with respect to any of the items
enumerated in clauses (a) through (j) of Item 4 of Schedule 13D and there can be
no assurance that any transaction or other change in Philips' MedQuist ownership
interest will occur as a result of such review.
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and supplemented as follows:
(a) As of the date hereof, Philips owns 26,085,086 Shares, which
constitutes approximately 69.6% of the outstanding Shares.
(b) Philips has sole voting and dispositive power over 26,085,086
Shares that it owns. The agreements pursuant to which Philips disclosed in
Amendment No. 3 to the Schedule 13D that it had shared voting and/or dispositive
power over 1,841,888 Shares have expired and Philips no longer has shared voting
and/or dispositive power over such 1,841,888 Shares.
-3-
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: July 6, 2007
KONINKLIJKE PHILIPS ELECTRONICS N.V.
By: /s/ G.J. KLEISTERLEE
----------------------------------------
Name: G.J. Kleisterlee
Title: President & CEO
By: /s/ P.J. SIVIGNON
----------------------------------------
Name: P.J. Sivignon
Title: Executive Vice President & CFO
-4-